Healthcare provider profile · identity verified

Khaled Al-Taieb, M.D.

Internal Medicine · YOUNGSTOWN, OH · NPI 1003144643

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	720	225
Amlodipine Besylate	Amlodipine Besylate	420	136
Losartan Potassium	Losartan Potassium	362	116
Rosuvastatin Calcium	Rosuvastatin Calcium	357	106
Metformin Hcl	Metformin Hcl	349	101
Lisinopril	Lisinopril	283	81
Tamsulosin Hcl	Tamsulosin Hcl	223	79
Metoprolol Succinate	Metoprolol Succinate	211	73
Jardiance	Empagliflozin	207	64
Levothyroxine Sodium	Levothyroxine Sodium	189	52
Omeprazole	Omeprazole	172	68
Nifedipine Er	Nifedipine	155	51
Simvastatin	Simvastatin	154	47
Gabapentin	Gabapentin	152	55
Ozempic	Semaglutide	152	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	132	20
Metoprolol Tartrate	Metoprolol Tartrate	129	38
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	128	128
Eliquis	Apixaban	125	41
Famotidine	Famotidine	118	39
Albuterol Sulfate Hfa	Albuterol Sulfate	113	36
Fluticasone Propionate	Fluticasone Propionate	106	49
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	102	29
Allopurinol	Allopurinol	101	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	101	33
Metformin Hcl Er	Metformin Hcl	97	26
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	85	29
Glipizide	Glipizide	82	26
Alendronate Sodium	Alendronate Sodium	79	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	22
Atenolol	Atenolol	75	22
Carvedilol	Carvedilol	75	25
Ezetimibe	Ezetimibe	75	22
Furosemide	Furosemide	75	31
Hydralazine Hcl	Hydralazine Hcl	75	25
Trulicity	Dulaglutide	68	13
Trazodone Hcl	Trazodone Hcl	66	26
Sertraline Hcl	Sertraline Hcl	65	21
Shingrix	Varicella-Zoster Ge/As01b/Pf	62	58
Pravastatin Sodium	Pravastatin Sodium	58	21
Potassium Chloride	Potassium Chloride	55	22
Warfarin Sodium	Warfarin Sodium	53	14
Hydrochlorothiazide	Hydrochlorothiazide	50	14
Chlorthalidone	Chlorthalidone	47	16
Felodipine Er	Felodipine	47	13
Diclofenac Sodium	Diclofenac Sodium	46	21
Finasteride	Finasteride	44	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	43	12
Triamcinolone Acetonide	Triamcinolone Acetonide	41	28
Clopidogrel	Clopidogrel Bisulfate	40	12
Azithromycin	Azithromycin	39	29
Spironolactone	Spironolactone	39	16
Duloxetine Hcl	Duloxetine Hcl	38	16
Pregabalin	Pregabalin	38	11
Methylprednisolone	Methylprednisolone	37	34
Methocarbamol	Methocarbamol	33	23
Lidocaine	Lidocaine	32	15
Clotrimazole	Clotrimazole	31	12
Pantoprazole Sodium	Pantoprazole Sodium	31	16
Alprazolam	Alprazolam	30	suppressed
Ibuprofen	Ibuprofen	30	15
Donepezil Hcl	Donepezil Hcl	29	suppressed
Ventolin Hfa	Albuterol Sulfate	29	19
Ketoconazole	Ketoconazole	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	13
Januvia	Sitagliptin Phosphate	25	11
Tizanidine Hcl	Tizanidine Hcl	25	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	22
Montelukast Sodium	Montelukast Sodium	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	23	suppressed
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Tdvax	Tetanus, Diphtheria Tox,adult	19	19
Cephalexin	Cephalexin	17	16
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Colchicine	Colchicine	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	15	suppressed
Estradiol	Estradiol	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Hydrocortisone	Hydrocortisone	13	11
Invokana	Canagliflozin	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Folic Acid	Folic Acid	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Mupirocin	Mupirocin Calcium	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error